13F HOLDINGS REPORT
Sanofi
Quarter ended Q1 2025 · Filed May 6, 2025 · Accession 0000950123-25-004066
Total Value
$165.9M
Positions
9
Other Managers
0
Confidential Omitted
No
Holdings (9)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | MeiraGTx Holdings plc | MGTX | 12,197,737 | $82.7M | 49.84% |
| 2 | Novavax | NVAX | 6,880,481 | $44.1M | 26.58% |
| 3 | Inhibrx Biosciences, Inc. | INBX | 1,157,926 | $16.2M | 9.76% |
| 4 | AnaptysBio | ANABV | 821,917 | $15.3M | 9.21% |
| 5 | Eledon | ELDN | 814,980 | $2.8M | 1.66% |
| 6 | LAVA Therapeutics N.V. | N51517105 | 1,919,455 | $2.4M | 1.47% |
| 7 | IGM Biosciences | 449585108 | 1,438,975 | $1.7M | 1.00% |
| 8 | Inozyme, Inc | 45790W108 | 443,255 | $403,362 | 0.24% |
| 9 | Q32 Bio Inc. | QTTB | 244,083 | $402,737 | 0.24% |